CTOs on the Move

Enveric Biosciences

www.enveric.com

 
Enveric Biosciences is a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of cancer treatments. Enveric Biosciences has set out with the goal of rigorously testing natural compounds, starting with cannabinoids, to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.enveric.com
  • 4851 Tamiami Trail N Suite 200
    Naples, FL USA 34103
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Enveric Biosciences raised $10M on 01/12/2021
Enveric Biosciences raised $12.8M on 02/09/2021

Similar Companies

Egalet

Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.

College Pharmacy

College Pharmacy is a Hamilton, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greenrise Global Brands

Greenrise is a Canadian publicly traded corporation with its representative office located in Hamburg, Germany and operates in the medical and CBD cannabis markets in Germany.

TMS International

TMSi is specialized in developing of high-quality measurement systems for electrophysiological parameters such as EEG and High Density EMG. Our systems are highly versatile and have the best data quality possible.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.